Auto-generated from public data. Not the firm's stated position.
Axilium Holding appears to focus on early-stage investments across biotech, edtech, hardware, and SaaS sectors, with recent portfolio activity suggesting particular interest in industrial AI, cell therapy manufacturing, and enterprise software solutions. The firm's disclosed check size of €0.1M to €1.5M and concentration on pre-seed and seed stages indicate a strategy targeting foundational technology companies in Northern Europe.
Generated 13 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.